ISRCTN14391248已完成4 期
A single-blind, phase IV UK multi-centre randomised controlled trial to determine reactogenicity and immunogenicity of COVID-19 vaccines administered concomitantly with seasonal influenza vaccines
niversity Hospitals Bristol NHS Foundation Trust0 个研究点目标入组 679 人开始时间: 2021年3月30日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 679
研究概览
简要总结
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34774197/ (added 15/11/2021) Other publications see attached file ISRCTN14391248_participant results_v1.0_01October2021.pdf [1.0] Summary of results for participants (added 17/03/2023) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38212836/ implementation (added 12/01/2024) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38263245/ statistical methodologies implementation (added 24/01/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged =18 years
- •2. Received one dose of either:
- •2.1. ChAdOx1 vaccine, 56 to 90 days prior to trial enrolment
- •2.2. BNT162b2 vaccine, 28 and 90 days prior to trial enrolment
- •3. Agree to refrain from blood donation in the 7 days following vaccination (at both visits 1 and 2)
- •4. Willing to allow their General Practitioner (GP) and consultant, if appropriate, to be notified of participation in the trial
- •5. Willing to allow investigators to discuss their medical history and confirm vaccination status with their GP, and access all medical records when relevant to trial procedures
- •6. Willing and able to give written informed consent for participation in the trial
- •7. Able to use and has access to an electronic device (such as a laptop, tablet, or smartphone) to complete trial procedures (such as the e-diary)
- •8. Able and willing to comply with all trial requirements, in the Investigator’s opinion
排除标准
- •Current exclusion criteria as of 07/05/2021:
- •1. Receipt of any vaccine (licensed or investigational) other than ChAdOx1 or BNT162b2 within 30 days before visit 1
- •2. Administration of immunoglobulins and/or any blood products within three months before visit 1
- •3. History of allergic disease or reactions likely to be exacerbated by any component of trial vaccines (for example hypersensitivity to the active substance or any of the SmPC-listed ingredients)
- •4. Bleeding disorder (e.g., factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venepuncture and any history of cerebral venous sinus thrombosis, acquired or hereditary thrombophilia, heparin-induced thrombocytopenia or antiphospholipid syndrome. Those who have experienced major venous and arterial thrombosis occurring with thrombocytopenia following vaccination with any COVID-19 vaccine should not receive a second dose of COVID-19 Vaccine AstraZeneca.
- •5. Continuous use of anticoagulants, such as coumarins and related anticoagulants (such as warfarin) or novel oral anticoagulants (such as apixaban, rivaroxaban, dabigatran, and edoxaban)
- •6. Suspected or known current alcohol or drug dependency
- •7. Any other significant disease, disorder, or finding which may significantly increase the risk to the participant, affect their ability to participate in the trial, or impair interpretation of the trial data
- •8. Current, active, and progressive neurological disorders (such as multiple sclerosis, Guillain-Barre syndrome, transverse myelitis). Bell’s palsy will not be an exclusion criterion
- •9. Scheduled elective surgery during trial participation if this interferes with the study protocol
- •10. Participated in another research trial involving an investigational product in the 12 weeks prior to visit 1, or if receipt of any IMP is planned during the trial period
- •11. Acute, ongoing respiratory illness (moderate or severe illness, with or without fever) at visit 1
- •12. Fever (oral temperature >37.8°C) at visit 1
- •Previous exclusion criteria:
- •1. Receipt of any vaccine (licensed or investigational) other than ChAdOx1 or BNT162b2 within 30 days before visit 1
- •2. Administration of immunoglobulins and/or any blood products within three months before visit 1
- •3. History of allergic disease or reactions likely to be exacerbated by any component of trial vaccines (for example hypersensitivity to the active substance or any of the SmPC-listed ingredients)
- •4. Bleeding disorder (for example factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venepuncture
- •5. Continuous use of anticoagulants, such as coumarins and related anticoagulants (such as warfarin) or novel oral anticoagulants (such as apixaban, rivaroxaban, dabigatran, and edoxaban)
- •6. Suspected or known current alcohol or drug dependency
- •7. Any other significant disease, disorder, or finding which may significantly increase the risk to the participant, affect their ability to participate in the trial, or impair interpretation of the trial data
- •8. Current, active, and progressive neurological disorders (such as multiple sclerosis, Guillain-Barre syndrome, transverse myelitis). Bell’s palsy will not be an exclusion criterion.
- •9. Scheduled elective surgery during trial participation if this interferes with the study protocol
- •10. Participated in another research trial involving a
研究者
相似试验
进行中（未招募）
2 期
Comparing COVID-19 vaccine schedule combinations in adolescents (Com-COV3)Prevention of COVID-19 infection in adolescents between 12-16 years of ageInfections and InfestationsCOVID-19 (SARS-CoV-2 infection)ISRCTN12348322niversity of Oxford429
进行中（未招募）
不适用
Randomised trial of LightPath Imaging in breast cancer surgeryCancerBreast cancerISRCTN17778965ightpoint Medical Ltd66
已完成
不适用
Mental health intervention for children with epilepsyChildren and young people with common mental health disorders and epilepsyMental and Behavioural DisordersISRCTN57823197Great Ormond Street Hospital for Children NHS Foundation Trust334
已完成
不适用
A patient and carer shared management intervention for anorexiaMental and Behavioural DisordersAnorexia nervosaISRCTN14644379South London and Maudsley NHS Foundation Trust380
进行中（未招募）
不适用
A pilot study to evaluate automatic deep vein thrombosis diagnostic softwareDeep vein thrombosisCirculatory SystemPhlebitis and thrombophlebitis of other deep vessels of lower extremitiesISRCTN11069056Oxford University Hospitals NHS Trust400